Journal Title：Expert Opinion On Therapeutic Targets

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

本期刊評(píng)估分子、信號(hào)通路、受體和其他治療靶點(diǎn)及其作為藥物開發(fā)候選物的潛力。本期刊上的文章側(cè)重于分子水平和早期臨床前研究。文章不應(yīng)包括臨床信息，包括特定藥物和臨床試驗(yàn)。

編輯歡迎：

涵蓋分子水平的新疾病靶點(diǎn)的評(píng)論以及有關(guān)早期臨床前研究及其對(duì)未來藥物開發(fā)的影響的信息。

文章不應(yīng)包括臨床信息，包括特定藥物和臨床試驗(yàn)。

原創(chuàng)研究論文，報(bào)告靶點(diǎn)選擇和驗(yàn)證研究的結(jié)果以及研究和上市藥物的基本作用機(jī)制研究。

讀者包括制藥行業(yè)的科學(xué)家、管理人員和決策者、分子醫(yī)學(xué)領(lǐng)域的學(xué)術(shù)研究人員以及其他密切參與研發(fā)的人員。

Expert Opinion On Therapeutic Targets創(chuàng)刊于2001年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋醫(yī)學(xué) - 藥學(xué)全領(lǐng)域，此刊是該細(xì)分領(lǐng)域中屬于非常不錯(cuò)的SCI期刊，在行業(yè)細(xì)分領(lǐng)域中學(xué)術(shù)影響力較大，專業(yè)度認(rèn)可很高，所以對(duì)原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)4.6，該期刊近期沒有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。